Chemically programmable immunity
AssigneeAltermune Technologies, LLC
InventorKary B. Mullis
Life of this patent
Estimating the term…
Abstract
The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in a human or animal that has been preimmunized against the first binding site, and (2) one or more second binding sites that bind specifically to a desired compound or molecule. The first binding site and the second binding site(s) are linked by a linker portion of the molecule.
Claims17
A composition for immunizing a human or animal to a target compound or molecule wherein the human or animal is immunologically naïve to the target compound or molecule comprising:
- an immunity linker molecule having
- (a) at least one first binding site that binds to an antibody produced by previous immunization of the human or animal with a polysaccharide that is not the target compound or molecule,
- (b) a linking portion and
- (c) at least one second binding site that binds to a target compound or molecule
- wherein the second binding site is an aptamer;
- wherein the composition contains an effective amount of immunity linker molecule that provides substantially immediate immunity to the target compound or molecule.
A method of establishing immediate immunity to a target in an individual comprising, administering to the individual an effective amount of a composition comprising one or more immunity linkers, wherein the immunity linkers comprise:
- a) at least one first binding site that binds to that binds to an antibody produced by previous immunization of the individual with a polysaccharide that is not the target compound or molecule,
- b) a linking portion, and
- c) at least one second binding site, wherein the second binding site is an aptamer nucleic acid, wherein the second binding site binds to the target, and wherein the individual has a pre-existing immunity to the first binding site.
Dependencies are inferred from the claim text.